Cohance Lifesciences Ltd (COHANCE) Q3FY26 Management Mirror - Dec-2025 Qtr
Revenue Outlook
Lowered (Dec'25 Qtr): Management revised FY26 revenue expectations downward to an "early to mid double-digit decline." This marks a significant deterioration from the Sep'25 Qtr, where guidance was lowered to "broadly flattish" versus FY25, and the Jun'25 Qtr, where growth guidance was reaffirmed.
Modified (Dec'25 Qtr): The latest revision is attributed to timing issues, product mix impacts, specifically destocking in two large commercial products, regulatory delays at Nacharam, and delayed reloads.
Reaffirmed (Dec'25 Qtr): Management remains committed to the long-term $1 billion revenue target by FY30, though admitted timing may shift slightly due to current challenges. This target has been consistent across all three quarters.
Reaffirmed (Dec'25 Qtr): FY27 is expected to return to growth, driven by pipeline build-up and API Plus recovery.
4 more themes on the ELITE plan.